Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 15 | GlobeNewswire (Europe) | SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
18.06. | Aktionäre von Zentalis Pharmaceuticals wählen drei Direktoren bei Jahreshauptversammlung | 2 | Investing.com Deutsch | ||
18.06. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
02.06. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 40 | GlobeNewswire (Europe) | SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
02.06. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
20.05. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
ZENTALIS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
14.05. | Zentalis Pharmaceuticals GAAP EPS of -$0.67 misses by $0.04 | 1 | Seeking Alpha | ||
14.05. | Zentalis Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
01.05. | Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 100 | GlobeNewswire (Europe) | SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
28.04. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
23.04. | Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
01.04. | Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 111 | GlobeNewswire (Europe) | SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1... ► Artikel lesen | |
27.03. | Stifel maintains Buy on Zentalis stock with $9 target | 2 | Investing.com | ||
27.03. | H.C. Wainwright sets $10 target for Zentalis shares, maintains Buy | 1 | Investing.com | ||
26.03. | Zentalis Pharmaceuticals GAAP EPS of -$2.33 beats by $0.13, revenue of $67.43M beats by $26.81M | 3 | Seeking Alpha | ||
26.03. | Zentalis Pharmaceuticals files $250M mixed securities shelf | 1 | Seeking Alpha | ||
26.03. | Zentalis Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
26.03. | Zentalis Pharmaceuticals, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
26.03. | Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates | 123 | GlobeNewswire (Europe) | Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part... ► Artikel lesen | |
25.03. | Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 | 1 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CUREVAC | 4,594 | +0,26 % | BioNTech schluckt CureVac! Evotec und Vidac als nächstes? Kurstreiber Übernahme und Kaufempfehlung | Steht bei Vidac Pharma eine neue Kursexplosion bevor? Im vergangenen Herbst ging es um rund 200 % nach oben. Gestern gab es eine Kaufempfehlung. Die Analysten sehen bei der Biotech-Perle Vervielfachungspotenzial.... ► Artikel lesen | |
MODERNA | 25,750 | +5,64 % | Code des Lebens entschlüsselt - so geht es weiter! Illumina, PanGenomic Health, Moderna | Erbinformationen sind die Baupläne des Lebens. Schon heute lassen sich mit Hilfe der Genomsequenzierung Informationen gewinnen, die unser Leben verlängern. Das gilt etwa, wenn wir bestimmte Vorprägungen... ► Artikel lesen | |
VALNEVA | 2,400 | +0,93 % | Valneva überträgt Impfstoffvertrieb in Deutschland an CSL | Valneva SE hat mit CSL Seqirus eine exklusive Vereinbarung über die Vermarktung und den Vertrieb seiner drei Impfstoffe in Deutschland geschlossen. Die Kooperation startet im Juli 2025 mit dem Chikungunya-Impfstoff... ► Artikel lesen | |
NOVAVAX | 5,820 | +3,89 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
NUREXONE BIOLOGIC | 0,469 | +4,92 % | Im Visier der Anleger: Künftiger Biotech Bluechip im Micro-Cap Kleid?! | ||
IMMUNITYBIO | 2,258 | +3,77 % | ImmunityBio, Inc.: ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom | Marketing authorization application for BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in situ (CIS) submitted to European Medicines Agency (EMA) in December 2024 and... ► Artikel lesen | |
ALDEYRA | 3,556 | +6,53 % | Aldeyra-Aktie steigt nach FDA-Vereinbarung zum Krebsmedikament-Studiendesign | ||
CARDIFF ONCOLOGY | 3,105 | +4,37 % | Cardiff Oncology, Inc. - 8-K, Current Report | ||
IOVANCE BIOTHERAPEUTICS | 1,533 | +4,15 % | Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week | ||
COHERUS ONCOLOGY | 0,657 | +2,62 % | Coherus Oncology, Inc.: Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc.... ► Artikel lesen | |
OCULAR THERAPEUTIX | 7,712 | -0,03 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company | BEDFORD, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, announced the launch... ► Artikel lesen | |
GUARDANT HEALTH | 43,110 | +0,21 % | Exas, Guardant, Gilead among gainers as Supreme Court ensures free preventive care | ||
ESPERION | 0,973 | +14,20 % | Esperion Therapeutics, Inc. - 8-K, Current Report | ||
VOYAGER THERAPEUTICS | 2,688 | +1,36 % | Voyager Therapeutics, Inc.: Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication | LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced... ► Artikel lesen | |
OPGEN | 2,600 | 0,00 % | OPGEN INC - 8-K, Current Report |